KR20220104496A - Composition for relieving hangover based on soybean curd residue micro-powder - Google Patents
Composition for relieving hangover based on soybean curd residue micro-powder Download PDFInfo
- Publication number
- KR20220104496A KR20220104496A KR1020210006874A KR20210006874A KR20220104496A KR 20220104496 A KR20220104496 A KR 20220104496A KR 1020210006874 A KR1020210006874 A KR 1020210006874A KR 20210006874 A KR20210006874 A KR 20210006874A KR 20220104496 A KR20220104496 A KR 20220104496A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- powder
- hangover
- relieving
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 239000000843 powder Substances 0.000 title claims abstract description 60
- 206010019133 Hangover Diseases 0.000 title claims abstract description 28
- 235000013527 bean curd Nutrition 0.000 title abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 69
- 230000000694 effects Effects 0.000 claims abstract description 36
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 claims abstract description 34
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims abstract description 34
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims abstract description 33
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims abstract description 33
- 229940041514 candida albicans extract Drugs 0.000 claims abstract description 18
- 239000012138 yeast extract Substances 0.000 claims abstract description 18
- 229920002261 Corn starch Polymers 0.000 claims abstract description 16
- 239000008120 corn starch Substances 0.000 claims abstract description 16
- 210000004369 blood Anatomy 0.000 claims abstract description 15
- 239000008280 blood Substances 0.000 claims abstract description 15
- 235000010841 Silybum marianum Nutrition 0.000 claims abstract description 14
- 241000320380 Silybum Species 0.000 claims abstract description 13
- 229940052016 turmeric extract Drugs 0.000 claims abstract description 10
- 235000020240 turmeric extract Nutrition 0.000 claims abstract description 10
- 239000008513 turmeric extract Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 23
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 22
- 244000163122 Curcuma domestica Species 0.000 claims description 14
- 235000003373 curcuma longa Nutrition 0.000 claims description 14
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 13
- 229940096421 milk thistle extract Drugs 0.000 claims description 13
- 235000020727 milk thistle extract Nutrition 0.000 claims description 13
- 235000013976 turmeric Nutrition 0.000 claims description 13
- 235000015872 dietary supplement Nutrition 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 229940099112 cornstarch Drugs 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000001965 increasing effect Effects 0.000 abstract description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 235000012754 curcumin Nutrition 0.000 description 13
- 229940109262 curcumin Drugs 0.000 description 13
- 239000004148 curcumin Substances 0.000 description 13
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 244000068988 Glycine max Species 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 108010073771 Soybean Proteins Proteins 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 235000019710 soybean protein Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- HMJSBVCDPKODEX-NXZHAISVSA-N (1e,6e)-1,7-bis(3,4-dimethoxyphenyl)hepta-1,6-diene-3,5-dione Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(OC)C(OC)=C1 HMJSBVCDPKODEX-NXZHAISVSA-N 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000013322 soy milk Nutrition 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 2
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- -1 etc.) Chemical compound 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 229960004245 silymarin Drugs 0.000 description 2
- 235000017700 silymarin Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000272459 Silybum marianum Species 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003028 enzyme activity measurement method Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
- A23L11/07—Soya beans, e.g. oil-extracted soya bean flakes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/212—Starch; Modified starch; Starch derivatives, e.g. esters or ethers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Agronomy & Crop Science (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
- Beans For Foods Or Fodder (AREA)
Abstract
Description
본 개시물에는 콩비지 미세분말 기반의 숙취 해소용 조성물이 개시된다.The present disclosure discloses a composition for relieving hangover based on okara fine powder.
숙취 현상은 간세포와 체내에 축적된 알코올 (alcohol) 및 아세트알데히드 (acetaldehyde)의 작용에 의해 발생한다. 정상적인 상태에서 소량의 알코올을 섭취할 경우 간 장내로 들어온 에탄올은 세포 사이토졸 (cytosol) 내의 알코올탈수소효소 (alcohol dehydrogenase, ADH)와 알데히드탈수소효소 (aldehyde dehydrogenase, ALDH)의 작용에 의해 아세테이트 (acetate)로 전환되고, 이는 순환계를 통해 간세포 밖으로 배설된다. 이중 특히 에탄올의 최초 대사산물인 아세트알데히드는 에탄올에 비해 반응성이 매우 높고 독성이 강하여 알코올성 간 장애의 주원인 물질인 것으로 알려져 있다.A hangover is caused by the action of alcohol and acetaldehyde accumulated in liver cells and the body. When a small amount of alcohol is ingested under normal conditions, the ethanol that enters the liver is converted into acetate by the action of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) in the cell cytosol. , which is excreted out of hepatocytes through the circulatory system. Among them, acetaldehyde, which is the first metabolite of ethanol, is known to be the main cause of alcoholic liver disorder because it has a very high reactivity and strong toxicity compared to ethanol.
일 측면에서, 본 개시물은 콩비지 미세분말 기반의 숙취 해소용 조성물을 제공하는 것을 목적으로 한다.In one aspect, an object of the present disclosure is to provide a composition for relieving hangover based on okara fine powder.
일 측면에서, 본 개시물은 강황 및 콩비지를 유효성분으로 포함하는 숙취 해소용 조성물을 제공한다.In one aspect, the present disclosure provides a composition for relieving a hangover comprising turmeric and okara as active ingredients.
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 강황 및 콩비지를 각각 2 내지 5 중량% 및 25 내지 40 중량%로 포함하는 것일 수 있다.In an exemplary embodiment, the composition may include 2 to 5% by weight and 25 to 40% by weight of turmeric and okara, respectively, based on the total weight of the composition.
예시적인 일 구현예에서, 상기 조성물은 효모, 옥수수전분 및 밀크씨슬을 더 포함하는 것일 수 있다.In an exemplary embodiment, the composition may further include yeast, corn starch and milk thistle.
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 효모, 옥수수전분 및 밀크씨슬을 각각 25 내지 40 중량%, 15 내지 25 중량% 및 3 내지 6 중량%로 포함하는 것일 수 있다.In an exemplary embodiment, the composition may include 25 to 40% by weight, 15 to 25% by weight, and 3 to 6% by weight of yeast, corn starch and milk thistle, respectively, based on the total weight of the composition.
예시적인 일 구현예에서, 상기 조성물은 강황 추출 분말, 콩비지 분말, 효모 추출 분말, 옥수수전분 및 밀크씨슬 추출 분말을 포함하는 것일 수 있다.In an exemplary embodiment, the composition may include turmeric extract powder, okara powder, yeast extract powder, corn starch and milk thistle extract powder.
예시적인 일 구현예에서, 상기 조성물은 강황 추출 분말, 콩비지 분말, 효모 추출 분말, 옥수수전분 및 밀크씨슬 추출 분말을 1 : 8 내지 10 : 8 내지 10 : 6 내지 8 : 1 내지 2의 중량비로 포함하는 것일 수 있다.In an exemplary embodiment, the composition comprises turmeric extract powder, okara powder, yeast extract powder, corn starch and milk thistle extract powder in a weight ratio of 1: 8 to 10: 8 to 10: 6 to 8: 1 to 2 may include.
예시적인 일 구현예에서, 상기 조성물은 혈액 내 알코올 함량을 감소시키는 것일 수 있다.In an exemplary embodiment, the composition may reduce the alcohol content in blood.
예시적인 일 구현예에서, 상기 조성물은 알코올탈수소효소 (ADH) 및 알데히드탈수소효소 (ALDH)의 활성을 증진시키는 것일 수 있다.In an exemplary embodiment, the composition may enhance the activity of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH).
다른 측면에서, 본 개시물은 숙취 해소용 조성물을 포함하는 숙취 해소용 건강보조식품을 제공한다.In another aspect, the present disclosure provides a dietary supplement for relieving hangover comprising a composition for relieving hangover.
예시적인 일 구현예에서, 상기 건강보조식품은 액상, 환제, 정제, 과립제, 산제 또는 캡슐제 제형을 갖는 것일 수 있다.In an exemplary embodiment, the health supplement may have a liquid, pill, tablet, granule, powder or capsule formulation.
일 측면에서, 본 개시물에 개시된 기술은 콩비지 미세분말 기반의 숙취 해소용 조성물을 제공하는 효과가 있다.In one aspect, the technology disclosed in the present disclosure has the effect of providing a composition for relieving a hangover based on okara fine powder.
도 1은 일 실험예에 따른 커큐민 복합체와 콩비지 혼합물의 HPLC 분석 전처리 과정을 나타낸 것이다.
도 2는 일 실험예에 따른 커큐민 복합체와 콩비지 혼합물의 HPLC 분석 전처리 사진을 나타낸 것이다.
도 3은 일 실험예에 따른 HPLC 분석 결과 440 nm chromatogram을 나타낸 것이다.
도 4는 일 실험예에 따른 in vitro 알코올탈수소효소 (ADH, Alcohol Dehydrogenase) 효소 활성 측정 결과를 나타낸 것이다.
도 5는 일 실험예에 따른 in vitro 알데히드탈수소효소 (ALDH, Aldehyde Dehydrogenase) 효소 활성 측정 결과를 나타낸 것이다.
도 6은 일 실험예에 따른 in vivo 혈중 알코올 농도 측정 결과를 나타낸 것이다.
도 7은 일 실험예에 따른 in vivo 알코올탈수소효소 (ADH, Alcohol Dehydrogenase) 효소 활성 측정 결과를 나타낸 것이다.
도 8은 일 실험예에 따른 in vivo 알데히드탈수소효소 (ALDH, Aldehyde Dehydrogenase) 효소 활성 측정 결과를 나타낸 것이다.1 shows a pretreatment process for HPLC analysis of a mixture of curcumin complex and okara according to an experimental example.
Figure 2 shows a picture of the pretreatment HPLC analysis of the curcumin complex and okara mixture according to an experimental example.
3 shows a 440 nm chromatogram as a result of HPLC analysis according to an experimental example.
Figure 4 shows the results of in vitro alcohol dehydrogenase (ADH, alcohol dehydrogenase) enzyme activity measurement according to an experimental example.
5 shows the results of measuring the activity of an aldehyde dehydrogenase (ALDH, Aldehyde Dehydrogenase) enzyme in vitro according to an experimental example.
6 shows the results of in vivo blood alcohol concentration measurement according to an experimental example.
7 shows the results of measuring the in vivo alcohol dehydrogenase (ADH, Alcohol Dehydrogenase) enzyme activity according to an experimental example.
8 shows the measurement results of in vivo aldehyde dehydrogenase (ALDH, Aldehyde Dehydrogenase) enzyme activity according to an experimental example.
이하, 본 개시물을 상세히 설명한다.Hereinafter, the present disclosure will be described in detail.
일 측면에서, 본 개시물은 강황 및 콩비지를 유효성분으로 포함하는 숙취 해소용 조성물을 제공한다.In one aspect, the present disclosure provides a composition for relieving a hangover comprising turmeric and okara as active ingredients.
강황 (Curcuma longa)은 생강과에 속하는 식물로서, 약용으로 쓰이는 뿌리줄기 쪽에 여러 가지 유용 성분이 함유되어 있으며, 가장 대표적인 성분으로는 커큐민이 있다. 상기 강황은 강황의 뿌리줄기로서, 예시적인 일 구현예에서, 상기 강황은 강황의 분말, 추출물 또는 추출물의 분말인 것일 수 있다.Turmeric ( Curcuma longa ) is a plant belonging to the ginger family, and contains various useful ingredients in the rhizome used for medicinal purposes, and the most representative ingredient is curcumin. The turmeric is a rhizome of turmeric, and in an exemplary embodiment, the turmeric may be a powder of turmeric, an extract, or a powder of an extract.
상기 강황 추출물은 당해 기술분야에 알려진 방법에 따라 직접 추출하여 제조할 수도 있고, 시판의 제품을 구입하여 사용할 수도 있다. 예시적인 일 구현예에서, 강황 추출물은 물, 탄소수 1 내지 4의 알코올 (예컨대, 메탄올, 에탄올, 프로판올, 부탄올 등), 에틸렌, 아세톤, 헥산, 에테르, 클로로포름, 에틸아세테이트, 부틸아세테이트, 디클로로메탄, N, N-디메틸포름아미드 (DMF), 염화메틸렌, 디메틸설폭사이드 (DMSO), 글리세린, 부틸렌글리콜, 프로필렌글리콜, 디프로필렌글리콜, 메틸렌클로라이드 및 디에틸에테르로 이루어진 군에서 선택되는 1 이상의 용매로 추출한 것일 수 있다.The turmeric extract may be prepared by direct extraction according to a method known in the art, or a commercially available product may be purchased and used. In an exemplary embodiment, the turmeric extract is water, an alcohol having 1 to 4 carbon atoms (eg, methanol, ethanol, propanol, butanol, etc.), ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, At least one solvent selected from the group consisting of N,N-dimethylformamide (DMF), methylene chloride, dimethyl sulfoxide (DMSO), glycerin, butylene glycol, propylene glycol, dipropylene glycol, methylene chloride and diethyl ether may have been extracted.
콩비지는 두부를 만들 때 두유를 짜고 남은 부산물을 의미한다. 예를 들어, 상기 콩비지는 콩단백에서 두유를 짜고 남은 부산물을 의미하는 것으로, 콩단백에서 수용성 단백질을 제거한 것일 수 있다. 상기 콩단백은 콩에서 기름을 빼고 남은 부산물을 의미하는 것으로, 착유 공정은 당업자가 당해 기술분야에 알려진 방법을 적절하게 선택하여 실시할 수 있다. 예를 들어, 상기 콩단백은 압착 콩단백으로, 유기용매 사용 없이 압착 방식으로, 예컨대 상온 압착 방식으로 콩에서 기름을 빼고 남은 부산물인 것일 수 있다.Soybean Beans are the by-products left after squeezing soymilk when making tofu. For example, the okara refers to a by-product left after squeezing soymilk from soybean protein, and may be obtained by removing water-soluble protein from soybean protein. The soybean protein refers to a by-product remaining after removing oil from soybeans, and the milking process may be performed by appropriately selecting methods known in the art by those skilled in the art. For example, the soybean protein may be a by-product remaining after removing oil from soybeans as a compressed soybean protein, for example, by a compression method without using an organic solvent, for example, a compression method at room temperature.
콩비지는 많은 양의 수용성 물질이 빠져 나간 상태이나, 양질의 단백질과 풍부한 섬유소를 비롯해 인체에 필요한 영양성분들을 포함하고 있다. 단백질 섭취량에 따른 체중 증가량의 비율을 나타내는 값인 단백질 효율비 (protein efficiency ratio, PER)가 대두, 두유 및 두부 중에서 가장 높은 우수한 단백질 자원이다. 또한, 콩비지는 여성 호르몬 에스트로겐과 유사 작용을 하는 이소플라본 (phytoestrogen)을 고함유하여 폐경기 증후군의 예방 및 치료에도 활용이 가능하다.Soybean okara is a state in which a large amount of water-soluble substances have escaped, but it contains nutrients necessary for the human body, including high-quality protein and abundant fiber. Protein efficiency ratio (PER), which is a value representing the ratio of weight gain according to protein intake, is the highest protein source among soybeans, soymilk and tofu. In addition, okara has a high content of isoflavones (phytoestrogen), which act similarly to the female hormone estrogen, and thus can be used for the prevention and treatment of menopause syndrome.
예시적인 일 구현예에서, 상기 콩비지는 건조 및 분쇄한 것일 수 있다.In an exemplary embodiment, the okara may be dried and pulverized.
예시적인 일 구현예에서, 상기 콩비지는 두부 제조 후 남은 부산물을 열풍건조한 후 미세분말화한 것일 수 있다.In an exemplary embodiment, the okara may be a fine powder after hot air drying the by-product remaining after manufacturing tofu.
예시적인 일 구현예에서, 상기 콩비지는 500 내지 2,000 mesh의 크기를 갖는 것일 수 있다. 다른 예시적인 일 구현예에서, 상기 콩비지는 500 mesh 이상, 600 mesh 이상, 700 mesh 이상, 800 mesh 이상, 900 mesh 이상 또는 1,000 mesh 이상이고, 2,000 mesh 이하, 1,900 mesh 이하, 1,800 mesh 이하, 1,700 mesh 이하, 1,600 mesh 이하, 1,500 mesh 이하, 1,400 mesh 이하, 1,300 mesh 이하, 1,200 mesh 이하 1,100 mesh 이하 또는 1,000 mesh 이하의 크기를 갖는 것일 수 있다. 예컨대, 상기 콩비지는 900 내지 1,100 mesh 또는 1,000 mesh의 크기를 갖는 것이 바람직할 수 있다.In an exemplary embodiment, the okara may have a size of 500 to 2,000 mesh. In another exemplary embodiment, the okara is 500 mesh or more, 600 mesh or more, 700 mesh or more, 800 mesh or more, 900 mesh or more, or 1,000 mesh or more, and 2,000 mesh or less, 1,900 mesh or less, 1,800 mesh or less, 1,700 mesh It may have a size of 1,600 mesh or less, 1,500 mesh or less, 1,400 mesh or less, 1,300 mesh or less, 1,200 mesh or less, 1,100 mesh or less, or 1,000 mesh or less. For example, the okara may preferably have a size of 900 to 1,100 mesh or 1,000 mesh.
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 강황 및 콩비지를 각각 2 내지 5 중량% 및 25 내지 40 중량%로 포함하는 것일 수 있다.In an exemplary embodiment, the composition may include 2 to 5% by weight and 25 to 40% by weight of turmeric and okara, respectively, based on the total weight of the composition.
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 강황을 2 중량% 이상, 3 중량% 이상 또는 4 중량% 이상이고, 5 중량% 이하, 4 중량% 이하 또는 3 중량% 이하로 포함하는 것일 수 있다.In an exemplary embodiment, the composition comprises 2 wt% or more, 3 wt% or more, or 4 wt% or more, and 5 wt% or less, 4 wt% or less, or 3 wt% or less of turmeric based on the total weight of the composition may be doing
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 콩비지를 25 중량% 이상, 28 중량% 이상, 31 중량% 이상 또는 34 중량% 이상이고, 40 중량% 이하, 37 중량% 이하, 34 중량% 이하 또는 31 중량% 이하로 포함하는 것일 수 있다.In an exemplary embodiment, the composition comprises 25 wt% or more, 28 wt% or more, 31 wt% or more, or 34 wt% or more, and 40 wt% or less, 37 wt% or less, 34 wt% or more of okara based on the total weight of the composition It may be included in wt% or less or 31 wt% or less.
예시적인 일 구현예에서, 상기 조성물은 효모, 옥수수전분 및 밀크씨슬을 더 포함하는 것일 수 있다.In an exemplary embodiment, the composition may further include yeast, corn starch and milk thistle.
효모는 빵, 맥주, 포도주 등을 만드는 데 사용되는 미생물로서, 곰팡이나 버섯 무리이지만 균사가 없고, 광합성능이나 운동성도 가지지 않는 단세포 생물을 총칭한다. 예시적인 일 구현예에서, 상기 효모는 건조 효모 분말, 효모 추출물 또는 효모 추출 분말인 것일 수 있다.Yeast is a microorganism used to make bread, beer, wine, etc. It is a group of fungi or mushrooms, but it is a generic term for single-celled organisms that do not have mycelium and do not have photosynthetic or motility. In an exemplary embodiment, the yeast may be dry yeast powder, yeast extract or yeast extract powder.
상기 건조 효모 분말은 건조 효모의 분말을 의미하는 것으로, 건조 효모는 효모가 수분이 많아 부패하기 쉬우므로 저장이 가능하도록 건조시킨 효모를 의미한다. 건조 효모는 효모가 죽지 않도록 건조시켜야 하며, 예시적인 일 구현예에서, 저온에서 통풍하여 건조시키는 방법, 약 30 ℃의 온도에서 8시간 동안 건조시키는 방법, 수평 방향으로 회전하는 건조통 속에서 통풍 건조시키는 방법 등 당해 기술분야에 알려진 방법에 따라 효모를 건조시킬 수 있으며, 열에 의한 효모의 사멸을 억제하기 위해 동결건조하는 것이 바람직할 수 있다.The dry yeast powder refers to a powder of dry yeast, and the dry yeast refers to a yeast dried so that it can be stored because the yeast has a lot of moisture and is easy to decay. Dry yeast should be dried so that the yeast does not die, and in one exemplary embodiment, a method of drying by ventilation at a low temperature, a method of drying at a temperature of about 30 ° C. for 8 hours, ventilation drying in a drying trough rotating in a horizontal direction The yeast may be dried according to methods known in the art, such as a method of making a lyophilization, and it may be preferable to freeze-drying in order to suppress the death of the yeast by heat.
상기 효모 추출물은 효모로부터 당해 기술분야에 알려진 방법에 따라 직접 추출하여 제조할 수도 있고, 시판의 제품을 구입하여 사용할 수도 있다. 예시적인 일 구현예에서, 상기 효모 추출물의 제조는 먼저 건조 효모에 효모 무게의 5배 내지 10배에 해당하는 물을 가하고 상온에서 1 내지 5 시간 동안 배양하여 효모를 활성화시킨 다음, 50 내지 88 ℃에서 0.5 내지 5 시간 동안 추출한 후 여과하여 효모 추출물을 얻을 수 있다. 또한, 수득한 효모 추출물을 고형분의 함량이 10% (w/v) 이상이 되도록 농축하고, 농축한 효모 추출물을 한외여과막으로 분자량 5,000 내지 20,000 달톤의 여과막이 장착된 시스템에서 여과한 후 이를 다시 농축하고 동결건조하여 효모 추출물을 얻을 수 있다.The yeast extract may be prepared by extracting directly from yeast according to a method known in the art, or may be used by purchasing a commercially available product. In an exemplary embodiment, in the preparation of the yeast extract, water corresponding to 5 to 10 times the weight of the yeast is first added to dry yeast and cultured for 1 to 5 hours at room temperature to activate the yeast, and then 50 to 88 ° C. After extraction for 0.5 to 5 hours, it is possible to obtain a yeast extract by filtration. In addition, the obtained yeast extract is concentrated so that the solid content is 10% (w/v) or more, and the concentrated yeast extract is filtered through an ultrafiltration membrane in a system equipped with a filtration membrane having a molecular weight of 5,000 to 20,000 Daltons, and then concentrated again and freeze-drying to obtain a yeast extract.
상기 효모 추출 분말은 효모 추출물의 분말을 의미한다.The yeast extract powder means a powder of yeast extract.
예시적인 일 구현예에서, 상기 옥수수전분은 옥수수전분 분말인 것일 수 있다.In an exemplary embodiment, the corn starch may be corn starch powder.
밀크씨슬 (Silybum marianum)은 국화과 식물로서, 열매와 씨에는 플라보노리그난이 함유되어 있으며 주요 구성 성분을 총칭하여 실리마린이라고 한다. 실리마린은 간 건강에 도움을 주는 것으로 알려져 있다. 예시적인 일 구현예에서, 상기 밀크씨슬은 밀크씨슬 분말, 밀크씨슬 추출물 또는 밀크씨슬 추출 분말인 것일 수 있다. 상기 밀크씨슬 추출 분말은 밀크씨슬 추출물의 분말을 의미한다. 예시적인 일 구현예에서, 상기 밀크씨슬은 밀크씨슬 종자의 분말, 추출물 또는 추출물의 분말인 것일 수 있다. Milk Thistle ( Silybum marianum ) is a plant in the Asteraceae family, and its fruits and seeds contain flavonolignans, and the main constituents are collectively called silymarin. Silymarin is known to support liver health. In an exemplary embodiment, the milk thistle may be milk thistle powder, milk thistle extract, or milk thistle extract powder. The milk thistle extract powder means a powder of milk thistle extract. In an exemplary embodiment, the milk thistle may be a powder of milk thistle seeds, an extract, or a powder of an extract.
상기 밀크씨슬 추출물은 당해 기술분야에 알려진 방법에 따라 직접 추출하여 제조할 수도 있고, 시판의 제품을 구입하여 사용할 수도 있다. 예시적인 일 구현예에서, 밀크씨슬 추출물은 물, 탄소수 1 내지 4의 알코올 (예컨대, 메탄올, 에탄올, 프로판올, 부탄올 등), 에틸렌, 아세톤, 헥산, 에테르, 클로로포름, 에틸아세테이트, 부틸아세테이트, 디클로로메탄, N, N-디메틸포름아미드 (DMF), 염화메틸렌, 디메틸설폭사이드 (DMSO), 글리세린, 부틸렌글리콜, 프로필렌글리콜, 디프로필렌글리콜, 메틸렌클로라이드 및 디에틸에테르로 이루어진 군에서 선택되는 1 이상의 용매로 추출한 것일 수 있다.The milk thistle extract may be prepared by direct extraction according to a method known in the art, or a commercially available product may be purchased and used. In an exemplary embodiment, the milk thistle extract is water, an alcohol having 1 to 4 carbon atoms (eg, methanol, ethanol, propanol, butanol, etc.), ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloro At least one selected from the group consisting of methane, N, N-dimethylformamide (DMF), methylene chloride, dimethyl sulfoxide (DMSO), glycerin, butylene glycol, propylene glycol, dipropylene glycol, methylene chloride and diethyl ether It may be extracted with a solvent.
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 효모, 옥수수전분 및 밀크씨슬을 각각 25 내지 40 중량%, 15 내지 25 중량% 및 3 내지 6 중량%로 포함하는 것일 수 있다.In an exemplary embodiment, the composition may include 25 to 40% by weight, 15 to 25% by weight, and 3 to 6% by weight of yeast, corn starch and milk thistle, respectively, based on the total weight of the composition.
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 효모를 25 중량% 이상, 28 중량% 이상, 31 중량% 이상 또는 34 중량% 이상이고, 40 중량% 이하, 37 중량% 이하, 34 중량% 이하 또는 31 중량% 이하로 포함하는 것일 수 있다.In an exemplary embodiment, the composition contains 25 wt% or more, 28 wt% or more, 31 wt% or more, or 34 wt% or more, 40 wt% or less, 37 wt% or less, 34 wt% or more, based on the total weight of the composition It may be included in wt% or less or 31 wt% or less.
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 옥수수전분을 15 중량% 이상, 18 중량% 이상 또는 21 중량% 이상이고, 25 중량% 이하, 23 중량% 이하, 21 중량% 이하 또는 19 중량% 이하로 포함하는 것일 수 있다.In an exemplary embodiment, the composition contains 15 wt% or more, 18 wt% or more, or 21 wt% or more, and 25 wt% or less, 23 wt% or less, 21 wt% or less, or It may be included in an amount of 19% by weight or less.
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 밀크씨슬을 3 중량% 이상, 4 중량% 이상 또는 5 중량% 이상이고, 6 중량% 이하, 5 중량% 이하 또는 4 중량% 이하로 포함하는 것일 수 있다.In an exemplary embodiment, the composition contains 3 wt% or more, 4 wt% or more, or 5 wt% or more, and 6 wt% or less, 5 wt% or less, or 4 wt% or less milk thistle based on the total weight of the composition may include.
예시적인 일 구현예에서, 상기 조성물은 강황 추출 분말, 콩비지 분말, 효모 추출 분말, 옥수수전분 및 밀크씨슬 추출 분말을 포함하는 것일 수 있다.In an exemplary embodiment, the composition may include turmeric extract powder, okara powder, yeast extract powder, corn starch and milk thistle extract powder.
예시적인 일 구현예에서, 상기 조성물은 강황 추출 분말, 콩비지 분말, 효모 추출 분말, 옥수수전분 및 밀크씨슬 추출 분말을 1 : 8 내지 10 : 8 내지 10 : 6 내지 8 : 1 내지 2의 중량비로 포함하는 것일 수 있다.In an exemplary embodiment, the composition comprises turmeric extract powder, okara powder, yeast extract powder, corn starch and milk thistle extract powder in a weight ratio of 1: 8 to 10: 8 to 10: 6 to 8: 1 to 2 may include.
예시적인 일 구현예에서, 상기 조성물은 혈액 내 알코올 함량을 감소시키는 것일 수 있다.In an exemplary embodiment, the composition may reduce the alcohol content in blood.
예시적인 일 구현예에서, 상기 조성물은 알코올탈수소효소 (ADH) 및 알데히드탈수소효소 (ALDH)의 활성을 증진시키는 것일 수 있다.In an exemplary embodiment, the composition may enhance the activity of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH).
다른 측면에서, 본 개시물은 숙취 해소용 조성물을 포함하는 숙취 해소용 건강보조식품을 제공한다.In another aspect, the present disclosure provides a dietary supplement for relieving hangover comprising a composition for relieving hangover.
예시적인 일 구현예에서, 상기 건강보조식품은 액상, 환제, 정제, 과립제, 산제 또는 캡슐제 제형을 갖는 것일 수 있다.In an exemplary embodiment, the health supplement may have a liquid, pill, tablet, granule, powder or capsule formulation.
이하, 실시예를 통하여 본 개시물을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 개시물을 예시하기 위한 것으로서, 본 개시물의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present disclosure will be described in more detail through examples. These examples are only for illustrating the present disclosure, and it will be apparent to those of ordinary skill in the art that the scope of the present disclosure is not to be construed as being limited by these examples.
실시예. 숙취 해소용 조성물 제조Example. Preparation of composition for relieving hangover
하기 표 1의 조성비에 따라 숙취 해소용 조성물을 제조하여 하기 실험예에서 사용하였다. 또한, 큐원㈜에서 상쾌환을 구입하여 이를 실시예 3의 양성 대조군으로 사용하였다.A composition for relieving a hangover was prepared according to the composition ratio of Table 1 below and used in the following experimental examples. In addition, SangKwa-Hwan was purchased from Q-One Co., Ltd. and used as a positive control in Example 3.
실험예 1. 커큐민 복합체와 콩비지 혼합물의 성분 분석Experimental Example 1. Component analysis of curcumin complex and okara mixture
강황의 주성분인 커큐민 (Curcumin) 70 내지 80 중량%, 디메톡시커큐민 (demethoxycurcumin, DMC) 15 내지 25 중량% 및 비스디메톡시 커큐민 (bisdemethoxy curcumin, BDMC) 2.5 내지 6.5 중량%를 포함하는 커큐민 복합체 (Curcumin C3 complex)와 상기 커큐민 복합체에 콩비지 분말을 첨가한 콩비지 혼합물의 성분을 분석하여 비교하였다.Curcumin complex comprising 70 to 80% by weight of curcumin, the main component of turmeric, 15 to 25% by weight of dimethoxycurcumin (DMC), and 2.5 to 6.5% by weight of bisdemethoxy curcumin (BDMC) C3 complex) and the components of the okara mixture in which okara powder was added to the curcumin complex were analyzed and compared.
상기 식에서,In the above formula,
커큐민은 R1=OCH3, R2=OCH3, MW=368이고,Curcumin is R 1 =OCH 3 , R 2 =OCH 3 , MW=368,
디메톡시커큐민은 R1=OCH3, R2=H, MW=338이고,Dimethoxycurcumin is R 1 =OCH 3 , R 2 =H, MW=338,
비스디메톡시 커큐민은 R1=H, R2=H, MW=308이다.Bisdimethoxy curcumin is R 1 =H, R 2 =H, MW=308.
구체적으로, 아래와 같이 3가지 종류의 시료를 준비하였다.Specifically, three types of samples were prepared as follows.
(1) 커큐민 복합체 (Curcumin C3 complex, 20 mg) + H2O (200 mL)(1) Curcumin C3 complex (20 mg) + H 2 O (200 mL)
(2) 콩비지 분말 (200 mg) + H2O (200 mL) (2) okara powder (200 mg) + H 2 O (200 mL)
(3) 콩비지 혼합물 (Curcumin C3 complex (20 mg) + 콩비지 분말 (200 mg)) + H2O (200 mL)(3) okara mixture (Curcumin C3 complex (20 mg) + okara powder (200 mg)) + H 2 O (200 mL)
상기 준비된 세 가지의 시료를 35 ℃에서 30분간 교반한 후, 에멀젼 1 mL을 취하여 MeOH 2 mL으로 희석한 다음 HPLC 분석하였다. 또한, 상기 준비된 세 가지의 시료를 35 ℃에서 30분간 교반한 후 초음파 균질기 (ultrasonic homogenizer)로 6,000 rpm으로 2분간 균질화하고, 에멀젼 1 mL을 취하여 MeOH 2 mL으로 희석한 다음 HPLC 분석하였다 (도 1 및 2 참조). HPLC 분석 조건은 아래와 같고, 그 결과를 도 3에 나타내었다.After stirring the three samples prepared above at 35° C. for 30 minutes, 1 mL of the emulsion was taken, diluted with 2 mL of MeOH, and analyzed by HPLC. In addition, the three samples prepared above were stirred at 35 ° C. for 30 minutes, homogenized for 2 minutes at 6,000 rpm with an ultrasonic homogenizer, and 1 mL of the emulsion was diluted with 2 mL of MeOH and then analyzed by HPLC (Fig. 1 and 2). HPLC analysis conditions are as follows, and the results are shown in FIG. 3 .
HPLC 분석 기기명 : Agilent 1200 seriesHPLC analysis instrument name: Agilent 1200 series
- Degasser: G1322A- Degasser: G1322A
- Pump: G1312A- Pump: G1312A
- Autosampler: G1329A- Autosampler: G1329A
- Column oven: G1316A- Column oven: G1316A
- Detector(DAD): G1315B- Detector (DAD): G1315B
용매 : 0.1% FA in ACN(A), 0.1% FA in Water(B)Solvent: 0.1% FA in ACN(A), 0.1% FA in Water(B)
기울기 : A: 0min(10%)-5min(10%)-40min(100%)-45min(100%)Slope: A: 0min(10%)-5min(10%)-40min(100%)-45min(100%)
컬럼 : YMC ODS-A C18/ 150x4.6mmI.D./ S-5um/ 12nmColumn: YMC ODS-A C18/ 150x4.6mmI.D./S-5um/ 12nm
컬럼 오븐 : 30 ℃Column oven: 30℃
유동률 : 0.7ml/minFlow rate: 0.7ml/min
주입량 : 10ulInjection volume: 10ul
HPLC monitored : 210, 254, 280, 330, 420 nmHPLC monitored : 210, 254, 280, 330, 420 nm
그 결과, 커큐민 복합체에 콩비지 분말을 첨가할 경우 커큐민 복합체의 화학 성분에 큰 차이를 보이는 것을 확인하였다.As a result, it was confirmed that when okara powder was added to the curcumin complex, there was a significant difference in the chemical composition of the curcumin complex.
실험예Experimental example 2. 2. ADHADH 및 and ALDHALDH 효소 활성 분석 ( Enzyme activity assay ( in vitroin vitro ))
알코올 대사에 관련된 효소인 ADH (Alcohol Dehydrogenase) 및 ALDH (Aldehyde Dehydrogenase)는 Sigma Chemical Co. (Saint Louis, Mo., USA)에서, 동결건조된 S9 rat liver homogenate는 MolTox Co. (North Carolina, USA)에서 구입하여 사용하였다.ADH (Alcohol Dehydrogenase) and ALDH (Aldehyde Dehydrogenase), enzymes involved in alcohol metabolism, are manufactured by Sigma Chemical Co., Ltd. (Saint Louis, Mo., USA), freeze-dried S9 rat liver homogenate was obtained from MolTox Co. (North Carolina, USA) was purchased and used.
ADH 효소 활성 측정은 Alcohol Dehydrogenase Activity Assay Kit (sigma, #MAK053)를 이용하여 제조사에서 제시한 방법에 따라 측정하였다. S9 rat liver fraction을 0.1% bovine serum albumin 용액에 용해시킨 후, 1 mg/mL의 단백질 농도로 제조하여 효소원으로 사용하였다. 시험 시료를 Kit에 포함되어 있는 Reaction mix (ADH assay buffer, Developer, 2M Ethanol)와 반응시켜 37 ℃에서 3시간 동안 1시간 마다 450 nm에서 흡광도의 변화를 측정하였다. ADH의 활성은 반응 종료 시의 최대 흡광도를 대조군의 최대 흡광도에 대한 상대적인 % activity를 구하였다. 이때 시료를 첨가하지 않은 것을 대조군으로 하였다.ADH enzyme activity was measured according to the method suggested by the manufacturer using Alcohol Dehydrogenase Activity Assay Kit (sigma, #MAK053). After dissolving S9 rat liver fraction in 0.1% bovine serum albumin solution, it was prepared at a protein concentration of 1 mg/mL and used as an enzyme source. The test sample was reacted with the reaction mix (ADH assay buffer, Developer, 2M Ethanol) included in the kit to measure the change in absorbance at 450 nm every hour for 3 hours at 37 °C. For the activity of ADH, the maximum absorbance at the end of the reaction was calculated as the relative % activity of the maximum absorbance of the control group. At this time, the sample to which no sample was added was used as a control.
ALDH 효소 활성 측정은 Aldehyde Dehydrogenase Activity Colorimetric Assay Kit (sigma, #MAK082)를 이용하여 제조사에서 제시한 방법에 따라 측정하였다. S9 rat liver fraction을 0.1% bovine serum albumin 용액에 용해시킨 후, 1 mg/mL의 단백질 농도로 제조하여 효소원으로 사용하였다. 시험 시료를 Kit에 포함되어 있는 Reaction mix (ALDH assay buffer, ALDH Substrate Mix, Acetaldehyde)와 반응시켜 실온에서 3시간 동안 1시간 마다 450 nm에서 흡광도의 변화를 측정하였다. ALDH 활성은 대조군에 대한 상대 활성 (%)으로 표시하였다. 이때 시료를 첨가하지 않은 것을 대조군으로 하였다.ALDH enzyme activity was measured according to the method suggested by the manufacturer using the Aldehyde Dehydrogenase Activity Colorimetric Assay Kit (sigma, #MAK082). After dissolving S9 rat liver fraction in 0.1% bovine serum albumin solution, it was prepared at a protein concentration of 1 mg/mL and used as an enzyme source. The change in absorbance at 450 nm was measured every hour for 3 hours at room temperature by reacting the test sample with the reaction mix (ALDH assay buffer, ALDH Substrate Mix, Acetaldehyde) included in the kit. ALDH activity was expressed as relative activity (%) relative to control. At this time, the sample to which no sample was added was used as a control.
그 결과, ADH 활성이 3시간 대에서 실시예 1 163%, 실시예 2 178% 및 실시예 3 172.1%를 보여 시료 미첨가를 대조군으로서 control을 100%로 하였을 때 시료 모두 ADH 활성이 증가하였으며, 특히 실시예 2 시료에서 ADH 활성이 가장 높게 증가하였다 (도 4 참조).As a result, the ADH activity of Example 1 163%, Example 2 178%, and Example 3 172.1% was shown in 3 hours, and when the control was set to 100% as a control, the ADH activity of all samples increased, In particular, the ADH activity was highest in the sample of Example 2 (see FIG. 4 ).
또한, 시료 미첨가를 대조군으로서 control을 100%로 하였을 때 ALDH 활성이 3시간 대에서 실시예 2 327%로 활성이 가장 촉진되었고, 실시예 1 201%, 실시예 3 305.4%로 활성이 증가함을 확인하였다 (도 5 참조). 실시예 2 시료는 아세트알데히드를 빠르게 분해시켜 숙취 해소 효과를 더욱 증진시키는 효과가 있음을 알 수 있었다.In addition, when the sample was not added as a control and the control was set to 100%, the ALDH activity was most promoted to 327% in Example 2 in 3 hours, and the activity increased to 201% in Example 1 and 305.4% in Example 3 was confirmed (see FIG. 5). The sample of Example 2 was found to have the effect of further enhancing the hangover relieving effect by rapidly decomposing acetaldehyde.
실험예 3. 혈중 알코올 농도, ADH 및 ALDH 효소 활성 분석 (Experimental Example 3. Analysis of blood alcohol concentration, ADH and ALDH enzyme activity ( in vivoin vivo ))
(1) 실험동물(1) Experimental animals
본 실험예에서 사용된 동물은 체중 260 내지 280 g의 생후 7주령 Sprague-Dawley (SD) 수컷 흰쥐를 (주)오리엔트사 (BioOrient Co., Seoul, Korea)에서 구입하여 1주일 동안 고형배합사료와 물로 예비사육시킨 후 체중이 280 내지 300 g에 도달하였을 때 실험을 수행하였다. 사육환경은 온도 25±2℃, 습도 50±5%를 유지시키고 12시간 간격으로 lightcycle을 유지하여 개개의 cage 안에서 사육하였다. 사육하는 동안 식이와 물은 충분히 공급하였다.The animals used in this experimental example were purchased from 7-week-old Sprague-Dawley (SD) male rats weighing 260 to 280 g from Orient Co. (BioOrient Co., Seoul, Korea) and fed with a solid compound feed for 1 week. The experiment was performed when the body weight reached 280 to 300 g after pre-breeding with water. In the breeding environment, the temperature was maintained at 25±2℃ and humidity of 50±5%, and the light cycle was maintained at 12-hour intervals to breed in individual cages. Food and water were provided adequately during breeding.
(2) 시료 제공 및 간 손상 유발(2) providing samples and causing liver damage
실험군은 정상군 (control), 알코올 투여군 (negative control), 실시예 1 투여군, 실시예 2 투여군, 실시예 3 투여군으로 총 5군으로 나누었으며 (표 2), 사료 섭취로 인해 알코올의 흡수 방해 현상을 배재하기 위하여 에탄올 투여 전 18시간 동안 절식시켰다. 각 시험 시료의 투여 방법은 시험 시료를 312 mg/Kg 농도로 D.W (Distilled water)에 조제하여 경구투여하였다. 30분 후 알코올을 3 g/Kg의 양으로 경구투여한 후 1, 3, 5시간에 심장에서 혈액을 채취하였다. 채취한 혈액은 4 M perchloric acid를 가해 최종 농도 1 M이 되게 조절하여 혼합한 후 4 ℃에서 5분 동안 방치한 후 13,000 rpm에서 2분간 냉장 상태로 원심분리하였다. 상등액 100 ul에 2M KOH 34 ul를 혼합하고 pH를 6.5 내지 8.0 사이로 조절한 후 4 ℃에서 30분 동안 방치하였다. 15,000 rpm에서 15분간 냉장 상태로 원심분리하여 단백질을 제거한 후, 상등액을 에탄올 측정 키트 (Sigma, #MAK076)를 이용하여 에탄올 농도를 측정하였다.The experimental group was divided into a total of 5 groups into a normal group (control), alcohol administration group (negative control), Example 1 administration group, Example 2 administration group, and Example 3 administration group (Table 2). In order to exclude ethanol, they were fasted for 18 hours before administration. For the administration method of each test sample, the test sample was prepared in D.W (distilled water) at a concentration of 312 mg/Kg and orally administered. After 30 minutes, alcohol was orally administered in an amount of 3 g/Kg, and blood was collected from the heart at 1, 3, and 5 hours. The collected blood was mixed with 4 M perchloric acid, adjusted to a final concentration of 1 M, and left at 4 °C for 5 minutes, and then centrifuged at 13,000 rpm for 2 minutes in a refrigerated state. 34 ul of 2M KOH was mixed with 100 ul of the supernatant, the pH was adjusted between 6.5 and 8.0, and then left at 4° C. for 30 minutes. After centrifugation at 15,000 rpm for 15 minutes in a refrigerated state to remove proteins, the ethanol concentration of the supernatant was measured using an ethanol measurement kit (Sigma, #MAK076).
(3) 간 조직의 ADH 및 ALDH 활성 측정(3) Measurement of ADH and ALDH activity in liver tissue
간 조직을 해동하여 D-PBS로 3회 세척한 후 조직 무게 (g) 10배의 0.1 M Tris-HCl buffer (pH 7.4)를 가하고 빙냉하에서 분쇄기로 균질화하여 준비하였다. 간 조직 균질액의 ADH와 ALDH 활성은 NAD+ 환원에 따른 NADH 생성량을 비색정량하여 측정하는 방법으로 제조된 assay kit (sigma, #MAK053, sigma, #MAK082)를 사용하여 측정하였고, 각 kit에서 제시한 계산식을 이용하여 milliunits/mL로 제시하였다.The liver tissue was thawed and washed three times with D-PBS, then 0.1 M Tris-HCl buffer (pH 7.4) of 10 times the tissue weight (g) was added, and homogenized with a grinder under ice cooling. The ADH and ALDH activities of the liver tissue homogenate were measured using an assay kit (sigma, #MAK053, sigma, #MAK082) prepared by colorimetric quantification of NADH production following NAD+ reduction. It was presented in milliunits/mL using the formula.
숙취 개선 효능을 확인하기 위해 Rat에 알코올을 단회 투여하여 1, 3, 5시간 후 혈액을 채취하여 혈중 알코올 농도를 측정하고, 간을 적출하여 ADH 및 ALDH 농도를 측정한 결과를 도 6 내지 8에 나타내었다.In order to confirm the effect of improving hangover, the results of measuring the ADH and ALDH concentrations by collecting the
혈중 알코올 농도는 음주 후 60 내지 90분 사이에 최고치를 나타낸다는 기존 보고와 같이 1시간 만에 혈중 알코올 농도가 최고치에 도달하였다. 에탄올 투여 후 1시간에서는 모든 시료에서 큰 변화가 없었지만, 에탄올 투여 3시간과 5시간에서 대부분의 시료들 모두 알코올 투여군에 비해 혈중 에탄올 농도가 감소하는 것을 확인하였다 (도 6 참조). 특히, 실시예 2 시료는 모든 시간에서 실시예 1 시료보다 혈중 알코올 농도를 더욱 감소시켰으며, 5시간에서 가장 낮은 혈중 알코올 농도를 나타내었다. 실시예 2 시료는 정상군에 비해 0.8배 정도 낮은 혈중 알코올 수치를 나타내었다.As previously reported that the blood alcohol concentration peaked between 60 and 90 minutes after drinking, the blood alcohol concentration reached the maximum within 1 hour. At 1 hour after ethanol administration, there was no significant change in all samples, but at 3 hours and 5 hours after ethanol administration, most of the samples showed a decrease in blood ethanol concentration compared to the alcohol administration group (see FIG. 6 ). In particular, the Example 2 sample further reduced the blood alcohol concentration than the Example 1 sample at all times, and exhibited the lowest blood alcohol concentration at 5 hours. The sample of Example 2 showed a blood alcohol level 0.8 times lower than that of the normal group.
ADH 활성은 3시간대에서 가장 높게 나타났으며, 정상군 (control, D.W)은 0.587±0.09 mU/mL, 실험군은 각각 2.687±0.82 mU/mL, 4.559±1.71 mU/mL, 4.105±1.70 mU/mL으로 나타났으며, 실시예 2 및 실시예 3 시료는 정상군보다 약 7.7배 및 6.9배 높은 ADH 활성을 나타내었다 (도 7 참조).ADH activity was highest at 3 hours, 0.587±0.09 mU/mL in the normal group (control, D.W), and 2.687±0.82 mU/mL in the experimental group, 4.559±1.71 mU/mL, and 4.105±1.70 mU/mL in the experimental group, respectively. , and the samples of Examples 2 and 3 exhibited about 7.7 times and 6.9 times higher ADH activity than the normal group (see FIG. 7 ).
또한, 에탄올 투여에 의해 간 조직의 ALDH 활성이 감소하였으나, 시험 시료의 투여에 따라 2시간대부터 ALDH 활성이 증가하였다. 구체적으로, 실험군은 각각 0.923±0.235 mU/mL, 1.229±0.366 mU/mL, 1.098±0.343 mU/mL의 ALDH 활성을 나타내어 정상군 (control, D.W)의 0.170±0.024 mU/mL보다 각각 5.4배, 7.2배, 6.4배 높은 활성을 나타내었다 (도 8 참조). 특히, 실시예 2 시료는 아세트알데히드를 빠르게 분해시켜 숙취 해소 효과를 더욱 증진시키는 효과가 있음을 확인하였다. 이는 in vitro에서 간 효소 ALDH 활성을 촉진시키는 결과와 일치하였다.In addition, the ALDH activity of the liver tissue was decreased by ethanol administration, but the ALDH activity increased from the 2nd time period according to the administration of the test sample. Specifically, the experimental group showed ALDH activity of 0.923±0.235 mU/mL, 1.229±0.366 mU/mL, and 1.098±0.343 mU/mL, respectively, 5.4 times higher than that of the normal group (control, D.W) 0.170±0.024 mU/mL, respectively, It exhibited 7.2-fold, 6.4-fold higher activity (see FIG. 8). In particular, it was confirmed that the sample of Example 2 has the effect of further enhancing the hangover relieving effect by rapidly decomposing acetaldehyde. This was consistent with the result of promoting liver enzyme ALDH activity in vitro.
이상, 본 개시물의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적인 기술은 단지 바람직한 실시 태양일 뿐이며, 이에 의해 본 개시물의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 개시물의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의해 정의된다고 할 것이다.Above, specific parts of the present disclosure have been described in detail, for those of ordinary skill in the art, these specific techniques are only preferred embodiments, and it is clear that the scope of the present disclosure is not limited thereby. something to do. Accordingly, it is intended that the substantial scope of the present disclosure be defined by the appended claims and their equivalents.
Claims (10)
A composition for relieving a hangover comprising turmeric and okara as active ingredients.
상기 조성물은 조성물 전체 중량을 기준으로 강황 및 콩비지를 각각 2 내지 5 중량% 및 25 내지 40 중량%로 포함하는 것인, 숙취 해소용 조성물.
The method of claim 1,
The composition is a composition for relieving a hangover, comprising 2 to 5% by weight and 25 to 40% by weight of turmeric and okara, respectively, based on the total weight of the composition.
상기 조성물은 효모, 옥수수전분 및 밀크씨슬을 더 포함하는 것인, 숙취 해소용 조성물.
The method of claim 1,
The composition further comprises yeast, corn starch and milk thistle, hangover relief composition.
상기 조성물은 조성물 전체 중량을 기준으로 효모, 옥수수전분 및 밀크씨슬을 각각 25 내지 40 중량%, 15 내지 25 중량% 및 3 내지 6 중량%로 포함하는 것인, 숙취 해소용 조성물.
4. The method of claim 3,
The composition is based on the total weight of the composition yeast, cornstarch and milk thistle 25 to 40% by weight, 15 to 25% by weight and 3 to 6% by weight, respectively, containing the composition for relieving a hangover.
상기 조성물은 강황 추출 분말, 콩비지 분말, 효모 추출 분말, 옥수수전분 및 밀크씨슬 추출 분말을 포함하는 것인, 숙취 해소용 조성물.
4. The method of claim 3,
The composition is a composition for relieving a hangover, comprising a turmeric extract powder, okara powder, yeast extract powder, corn starch and milk thistle extract powder.
상기 조성물은 강황 추출 분말, 콩비지 분말, 효모 추출 분말, 옥수수전분 및 밀크씨슬 추출 분말을 1 : 8 내지 10 : 8 내지 10 : 6 내지 8 : 1 내지 2의 중량비로 포함하는 것인, 숙취 해소용 조성물.
6. The method of claim 5,
The composition contains turmeric extract powder, okara powder, yeast extract powder, corn starch and milk thistle extract powder in a weight ratio of 1: 8 to 10: 8 to 10: 6 to 8: 1 to 2, hangover relief for composition.
상기 조성물은 혈액 내 알코올 함량을 감소시키는 것인, 숙취 해소용 조성물.
The method of claim 1,
The composition is to reduce the alcohol content in the blood, a composition for relieving a hangover.
상기 조성물은 알코올탈수소효소 (ADH) 및 알데히드탈수소효소 (ALDH)의 활성을 증진시키는 것인, 숙취 해소용 조성물.
The method of claim 1,
The composition is to enhance the activity of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), a composition for relieving a hangover.
A health supplement for relieving a hangover comprising the composition for relieving a hangover according to any one of claims 1 to 8.
상기 건강보조식품은 액상, 환제, 정제, 과립제, 산제 또는 캡슐제 제형을 갖는 것인, 숙취 해소용 건강보조식품.10. The method of claim 9,
The health supplements are liquid, pills, tablets, granules, powders or capsules that have a formulation, a hangover health supplement.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210006874A KR102642811B1 (en) | 2021-01-18 | 2021-01-18 | Composition for relieving hangover based on soybean curd residue micro-powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210006874A KR102642811B1 (en) | 2021-01-18 | 2021-01-18 | Composition for relieving hangover based on soybean curd residue micro-powder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220104496A true KR20220104496A (en) | 2022-07-26 |
| KR102642811B1 KR102642811B1 (en) | 2024-03-05 |
Family
ID=82609868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210006874A KR102642811B1 (en) | 2021-01-18 | 2021-01-18 | Composition for relieving hangover based on soybean curd residue micro-powder |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102642811B1 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1893933A (en) * | 2003-11-19 | 2007-01-10 | 奥加生物药业(I.P.1)有限公司 | Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers |
| KR100903690B1 (en) | 2007-12-18 | 2009-06-18 | 주식회사 엠에이치투 바이오케미칼 | Composition containing ornithine for relieving hang-over and alcohol liquor containing ornithine |
| CN101528240A (en) * | 2006-10-16 | 2009-09-09 | 宝生物工程株式会社 | Activity enhancer for detoxifying enzyme |
| KR20140026737A (en) * | 2012-08-23 | 2014-03-06 | 한국인스팜(주) | A composition comprising the powder of fermented curcuma longa l. for protecting alcoholic liver damage |
| KR20150028664A (en) * | 2013-09-06 | 2015-03-16 | 한미약품 주식회사 | Food composition for relieving hangover |
| KR20170009100A (en) * | 2015-07-15 | 2017-01-25 | 유니젠, 인크. | Compositions and medical compositions for treatment of and maintaining the health of the liver |
| KR20190125735A (en) * | 2018-04-30 | 2019-11-07 | 동아제약 주식회사 | Composition for hepatoprotective activity comprising Turmeric extract solution and Rice Soybean extract |
-
2021
- 2021-01-18 KR KR1020210006874A patent/KR102642811B1/en active IP Right Grant
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1893933A (en) * | 2003-11-19 | 2007-01-10 | 奥加生物药业(I.P.1)有限公司 | Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers |
| CN100391448C (en) * | 2003-11-19 | 2008-06-04 | 奥加生物药业(I.P.1)有限公司 | Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers |
| CN101528240A (en) * | 2006-10-16 | 2009-09-09 | 宝生物工程株式会社 | Activity enhancer for detoxifying enzyme |
| KR100903690B1 (en) | 2007-12-18 | 2009-06-18 | 주식회사 엠에이치투 바이오케미칼 | Composition containing ornithine for relieving hang-over and alcohol liquor containing ornithine |
| KR20140026737A (en) * | 2012-08-23 | 2014-03-06 | 한국인스팜(주) | A composition comprising the powder of fermented curcuma longa l. for protecting alcoholic liver damage |
| KR20150028664A (en) * | 2013-09-06 | 2015-03-16 | 한미약품 주식회사 | Food composition for relieving hangover |
| KR20170009100A (en) * | 2015-07-15 | 2017-01-25 | 유니젠, 인크. | Compositions and medical compositions for treatment of and maintaining the health of the liver |
| KR20190125735A (en) * | 2018-04-30 | 2019-11-07 | 동아제약 주식회사 | Composition for hepatoprotective activity comprising Turmeric extract solution and Rice Soybean extract |
Non-Patent Citations (2)
| Title |
|---|
| J Med Food vol.12(6), pp.1359-1367(2009.12.30.) * |
| 유재영 외 5명, Effects of DA-5513 on alcohol metabolism and alcoholic fatty liver in rats, Lab Anim Res Vol. 34, No. 2, 2018년 6월* * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102642811B1 (en) | 2024-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112244299B (en) | Probiotic composition with function of relieving nonalcoholic fatty liver and preparation method thereof | |
| KR101793123B1 (en) | preparing method of fermented soybean enhancing physiological active substance and the physiological active substance thereby | |
| KR20140137549A (en) | A EXTRACTING METHOD Hovenia dulcis FOR ACTIVATING ALCOHOL METABOLISM AND RELIEVING A HANGOVER AND HEALTHY FUNCTIONAL FOOD CONTAINING THE SAME | |
| JP5943406B2 (en) | Composition for maintaining the survival of bifidobacteria or lactic acid bacteria | |
| KR101253658B1 (en) | Manufacturing method of treated puffing and fermentation red ginseng concentrate | |
| KR101100337B1 (en) | Manufacturing method of granular tea using Phellinus linteus | |
| KR101040716B1 (en) | Feed additives using orostachys japonicus and feed composition, functional egg | |
| CN111919976A (en) | Feed additive for rabbits and application and preparation method thereof | |
| US9408812B2 (en) | Coenzyme Q10-containing composition for oral ingestion | |
| KR20220104496A (en) | Composition for relieving hangover based on soybean curd residue micro-powder | |
| US20140377388A1 (en) | Cholesterol discharge-accelerating agent and neutral fat discharge-accelerating agent using sunflower pith | |
| JP2003252775A (en) | Nk cell activation agent | |
| KR102135801B1 (en) | JELLY COMPRISING Phellinus linteus EXTRACT IMPROVED ANTIOXIDANT ACTIVITY AND METHOD FOR PREPARING THE SAME | |
| CN111903840A (en) | Compound ginkgo leaf feed additive rich in probiotics | |
| KR101313114B1 (en) | Manufacturing method of powder fermentatiom Opunita humifusa | |
| JP4115183B2 (en) | Feed additive, feed and egg to which it is added | |
| JP2004244396A (en) | Tnf-alpha production inhibitor | |
| KR101151706B1 (en) | Anti-oxidative feed composition comprising hempseed extract for fruit fly and preparation method thereof | |
| KR102040405B1 (en) | Food Composition for Including Extracts of Tetragonia tetragonioides Having Anti-Obese and Preparation for Thereof | |
| KR101847995B1 (en) | Method for producing black Gastrodia elata pill with increased functionality and taste | |
| TW202306579A (en) | Red yeast rice and composition containing specific components | |
| KR101692358B1 (en) | Composition for prevention or treatment of fatty liver comprising lysimachia vulgaris extract | |
| Boroojeni | Russian Olive as a Functional Food Ingredient-Post Harvest Processing Development and Optimization | |
| KR20140006750A (en) | Extract from salted and fermented shrimp, manufacturing method of the same and composition containing the same | |
| KR20230080848A (en) | Composition for preventing or improving obesity, fatty liver or steatohepatitis comprising hydroferulic acid drived from Momordica charantia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |